Quality of Life in Patients With Inoperable Malignant Bowel Obstruction

Summary

The primary objective of the study is to evaluate the impact on quality of life of Lanreotide Autogel 120 mg in combination with standard care, in comparison to the standard care alone, in subjects affected by inoperable malignant bowel obstruction.

Timeline

Start

2015-01

Primary completion

2018-01-16

Completion

2018-01-16

Outcome

Missed primary endpoint

Stopped (Enrollment): “The study was terminated early due to insufficient recruitment.”

registry analysis (superiority test); Standard Care vs Standard Care + Lanreotide Autogel; p =0.5396; Adjusted LS Mean Difference -11 (95% CI -47 to 25); ANCOVA NCT02365584 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lanreotide	Other / unclassified	120 mg	Subcutaneous

Indications